Hepatic Encephalopathy: Achieving Care Goals in the Acute Setting and Beyond




Hepatic encephalopathy (HE) is a commonly occurring complication of liver disease with the potential to cause severe impairments in brain function and substantially diminished overall quality of life. In the absence of appropriate treatment, it is associated with poor survival and a high risk of recurrence and hospitalization. Although treatment of patients presenting with acute overt HE appears to be generally aligned with expert recommendations, there remains a significant need for earlier disease intervention, as well as greater diligence in the provision of secondary prophylaxis following an overt HE episode. This program has been designed to provide hospital-based clinicians with knowledge and competence to assess and diagnosis HE early, review available treatment and trial data for available therapies, and develop care plans that incorporate transitional care strategies to impact outcomes outside the hospital setting.


Jasmohan Bajaj, MD, MS
Professor of Medicine
Divisions of Internal Medicine and Gastroenterology,
Hepatology, and Nutrition
Virginia Commonwealth University
McGuire VA Medical Center
Richmond, Virginia


Release date: April 13, 2021
Expiration date: April 13, 2022
Estimated time to complete activity: 1.0 hour



This educational initiative has been designed for physicians and other healthcare professionals who practice in hospital and internal medicine settings.


Upon completion of this educational activity, participants should be able to:

  • Describe an approach to the early diagnosis of hepatic encephalopathy (HE) that is consistent with current guideline recommendations
  • Summarize clinical trial data on the efficacy and safety of options for acute treatment and prophylaxis of HE
  • Implement a transitional care plan to prevent future hospitalizations of patients with HE

There are no fees for participating and receiving CME credit for this online activity.

During the period of April 13, 2021 through April 13, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.




Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or hms@integrityce.com.


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.


Integrity Continuing Education, Inc. requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following Integrity Continuing Education, Inc. planners and managers reported no financial relationships nor relationships to products or devices with ineligible companies related to the content of this CME activity: Donna Fausak and Patima Tanapat, PhD.


Jasmohan Bajaj, MD, MS
Consulting Fees: Kaleido Biosciences
Contracted Research: Cosmo Pharmaceuticals, Grifols, S.A., Valeant Pharmaceuticals


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


This CME activity is provided by Integrity Continuing Education, Inc.


This activity is supported by an educational grant from Salix Pharmaceuticals, Inc.


Continue to Pretest